Trulieve Cannabis (TRLV) Stock Hit By Harvest Accounting Distortion

The market shaved about 2.8% off Trulieve Cannabis stock today, yet the headline from this quarter is not a demand problem. The story is the hit to reported earnings from the Harvest deconsolidation and the way it distorts the income statement.

Trulieve posted a reported net loss of about US$406 million for Q2 on revenue of US$271 million. However, management pointed to roughly US$20 million of underlying net income once the one time Harvest impact is stripped out. For a medical cannabis operator that lives and dies on cash flow and margins, that gap between optical loss and core profitability is what matters most.

Love that Trulieve Cannabis is still generating underlying net income but uneasy about how one off hits can distort the headline loss picture? Check out the list of solid balance sheet and fundamentals stocks (49 results).

Q2 2026 Earnings Summary

• Revenue (Q2 2026 vs. Q2 2025): US$271 million vs. US$302.1 million (Revenue declined about 10.3%)
• Net Income or Loss (Q2 2026 vs. Q2 2025): Net loss of US$405.3 million vs. net loss of US$13.5 million (Loss widened very significantly)
• Basic EPS (Q2 2026 vs. Q2 2025): Loss of US$2.10 per share vs. loss of US$0.07 per share (Per share loss widened very significantly)
• Gross Margin (Q2 2026, consolidated vs. medical only): 60% consolidated compared with 63% for medical only (Medical operations are running at a higher margin than the group average)

Prefer clean visuals instead of another wall of earnings tables and footnotes? Get a full picture of Trulieve Cannabis with an at-a-glance view of its balance sheet strength in the company report for Trulieve Cannabis.

Bull Case on Trulieve’s Cash and Schedule III Tested

Bulls argue Trulieve Cannabis is a cash generative, federally aligned medical platform that can turn rescheduling and DEA registration into lasting earnings power. Q2 supports parts of that story. Medical only revenue of US$222 million grew sequentially and carried a 63% gross margin, while adjusted EBITDA of US$98 million and operating cash flow of US$53 million back the idea of a self funded model. A cash balance of US$325 million against US$289 million of debt and only US$21 million of capex in the quarter also fits the “healthy balance sheet” narrative. DEA registration progress and NYSE listing are clear structural milestones. However, consolidated revenue of US$271 million sat below last year’s US$302.1 million, which shows the growth leg of the bull thesis is not yet proven in the reported top line.

Bear Case on Structural Risk and Earnings Quality

Bears focus on regulatory dependence, earnings quality and the risk that capital projects and M&A fail to pay off. The GAAP net loss of US$405.3 million in Q2 will reinforce concerns that reported earnings are fragile, even if management attributes roughly US$407 million of that to one time Harvest deconsolidation. Revenue declined about 10.3% year on year while basic EPS loss widened sharply from US$0.07 to US$2.10, which lines up with worries about headline volatility and potential investor fatigue. Guidance that full year operating cash flow is now expected to be at least US$225 million, lowered from US$250 million, also shows some cash expectations being trimmed while capex guidance rises to US$95 million. The absence of any Q2 activity under the US$50 million buyback authorization can support scepticism about how aggressively Trulieve will actually deploy capital in shareholders’ favor.

After a GAAP loss this large, a trimmed cash flow outlook, and a volatile share price, it is fair to ask whether Trulieve Cannabis is only showing part of the story. Review the independent risk analysis for Trulieve Cannabis which shows 1 important warning sign

Stay Ahead With Simply Wall St

If the gap between Trulieve Cannabis’ headline GAAP loss and its underlying cash generation has you watching closely, register for free with Simply Wall St and add it to a Watchlist to track the share price against fair value and spot a potential entry that fits your plan. Once you hold the stock, keep your decisions grounded in data by using the Portfolio Command Center to cut through noise and surface only key developments that affect your thesis. For a longer term view, tap into crowd insights and sentiment through the Community and see how other investors are thinking about risks and opportunities. By surfacing hidden catalysts and red flags early, Simply Wall St helps you stay prepared and a step ahead of the market.

Seeking Alternatives Beyond Trulieve Cannabis

Fresh stock ideas do not stay under the radar for long. Once momentum builds, entry points can get away fast. Scan these curated lists before the crowd and get in early.

• Chase income opportunities that aim to keep payouts flying while share prices move by using a curated set of 8 dividend fortresses built for income focused investors.
• Spot early movers in critical materials before interest catches up by scanning a focused group of 28 best rare earth metal stocks tied to long term supply themes.
• Ride structural demand for smarter infrastructure by reviewing a hand picked collection of 36 power grid technology and infrastructure stocks positioned around grid upgrades and electrification trends.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com